Gyre Therapeutics, Inc. GYRE Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $17.9M+121% | -$85.48M-937% | -$8.24M+90.6% | ||
| $2.48M+60.2% | $1.55M+44.2% | $1.07M-1.2% | $1.09M+275% | ||
| $7.16M+761% | $831K-88.6% | $7.28M-45.5% | $13.37M+293% | ||
| —— | —— | —— | —— | ||
| —— | —— | -$285K— | —— | ||
| $3.7M+73.1% | $2.14M+222% | -$1.75M-299% | $879K— | ||
| —— | —— | —— | —— | ||
| —— | —— | $1.45M— | —— | ||
| —— | -$520K— | —— | —— | ||
| -$47K-304% | $23K— | —— | —— | ||
| —— | —— | —— | -$1.34M— | ||
| —— | -$816K-72.5% | -$473K-10.3% | -$429K— | ||
| —— | —— | $25.89M+143% | $10.68M+113% | ||
| $1.19M-50.0% | $2.38M-72.1% | $8.52M+70.9% | $4.99M— | ||
| —— | —— | —— | —— | ||
| $30K-92.6% | $406K— | —— | —— | ||
| $737K— | —— | $69K+431% | $13K— | ||
| —— | $1.69M+68.6% | $1M-24.9% | $1.33M— | ||
| —— | -$19.88M+5.8% | -$21.1M-52.7% | -$13.81M-129% | ||
| $2.36M— | —— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $24.38M+1,060% | $2.1M-15.9% | $2.5M— | —— | ||
| $343K— | —— | —— | -$1.89M— | ||
| —— | -$21.7M-360% | $8.33M— | —— | ||
| $5.62M-34.0% | $8.52M+34.2% | $6.35M+0.6% | $6.31M— | ||
| -$28K-103% | $1.05M+65.2% | $633K— | —— | ||
| —— | —— | $633K+256% | $178K— | ||
| -$63K-137% | $170K— | —— | $22K— | ||
| —— | $239K+513% | $39K— | —— | ||
| —— | $239K+513% | $39K— | —— | ||
| -$1.11M-10.7% | -$1M+13.6% | -$1.16M-38.4% | -$838K— | ||
| -$77K— | —— | -$1.31M-424% | -$251K— | ||
| —— | —— | $1.45M-24.5% | $1.91M— | ||
| -$1K+98.8% | -$83K— | —— | —— | ||
| —— | —— | —— | -$1.34M— | ||
| —— | -$520K— | —— | —— | ||
| —— | —— | —— | —— | ||
| $777K+15.6% | $672K+89.3% | $355K-12.1% | $404K— | ||
| —— | $1.69M+68.6% | $1M-24.9% | $1.33M— | ||
| $737K— | —— | $69K+431% | $13K— | ||
| $14.01M-9.4% | $15.47M-1.7% | $15.74M+110% | $7.48M— | ||
| $30K-92.6% | $406K— | —— | —— | ||
| $343K— | —— | —— | -$1.89M— | ||
| -$2.71M+62.2% | -$7.17M-177% | $9.26M— | —— | ||
| $1.15M-71.5% | $4.03M+462% | -$1.11M— | —— | ||
| $5.62M-34.0% | $8.52M+34.2% | $6.35M+0.6% | $6.31M— | ||
| -$180K— | —— | $17.38M+205% | $5.69M— | ||
| -$180K— | —— | $17.38M+205% | $5.69M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gyre Therapeutics, Inc. generate?
- Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
- What is Gyre Therapeutics, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
- Where does Gyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
